|
DOSAGE
|
External ophthalmic infections (Mild to Moderate): Instill 1/2" ribbon q8-12hours.
|
|
External ophthalmic infections (Severe): Instill 1/2" ribbon q3-4hrs until improvement occurs, following which treatment should be reduced prior to discontinuation.
|
|
INDICATIONS
|
TOBREX® (tobramycin ophthalmic ointment) 0.3 % is a topical antibiotic indicated in the treatment of external infections of the eye and its adnexa caused by susceptible bacteria. Clinical studies have shown tobramycin to be safe and effective for use in children
|
|
MECHANISM OF ACTION
|
Aminoglycoside: Prevents bacterial protein synthesis (binds to ribosome s30 or s50)
|
|
MICROBIOLOGY
|
Active against a wide variety of gram-negative and gram-positive bacteria includings some penicillin-resistant and gentamicin-resistant strains. Tobramycin is active against susceptible strains of the following microorganisms: Staphylococci, including S. aureus and S. epidermidis (coagulase-positive and coagulase-negative), including penicillin-resistant strains. Streptococci, including some of the Group A-beta-hemolytic species, some nonhemolytic species, and some Streptococcus pneumoniae. Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Enterobacter aerogenes, Proteus mirabilis, Morganella morganii, most Proteus vulgaris strains, Haemophilus influenzae and H. aegyptius, Moraxella lacunata, Acinetobacter calcoaceticus and some Neisseria species. Bacterial susceptibility studies demonstrate that in some cases, microorganisms resistant to gentamicin retain susceptibility to tobramycin.
|
|
CONTRAINDICATIONS & WARNINGS
|
TOBREX (tobramycin ophthalmic ointment) 0.3 % is contraindicated in patients with known hypersensitivity to any of its components.
|
|
PEDIATRIC USE
|
Safety and effectiveness in pediatric patients below the age of 2 months has not been established.
|
|
PREGNANCY
|
Category B: Reproduction studies in three types of animals at doses up to thirty-three times the normal human systemic dose have revealed no evidence of impaired fertility or harm to the fetus due to tobramycin. There are, however, no adequate and well-controlled studies in pregnant women. Because animal studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.
|
|
NOTE
|
Preservative chlorobutanol, increasing resistance from community-acquired infections. Aminoglycoside toxicity possible with pre-sensitized pts. or with extended use. Polysporin is the usual alternative.
|
